MDA435/LCC6 and MDA435/LCC6MDR1: Ascites Models of Human Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Jan 1

PMID 8546900

Citations 29

Authors

F Leonessa

D Green

T Licht

A Wright

J Lippman

M M Gottesman

R Clarke

Affiliations

Soon will be listed here.

Abstract

We have established a novel ascites tumour model (MDA435/LCC6) from the oestrogen receptor-negative, invasive and metastatic MDA-MB-435 human breast cancer cell line. MDA435/LCC6 cells grow as both malignant ascites and solid tumours in vivo in nude mice and nude rats, with a tumour incidence of approximately 100%. Untreated mice develop ascites following i.p. inoculation of 1 x 10(6) cells and have a reproducible life span of approximately 30 days, with all animals dying within a 48 h period. The in vivo response of MDA435/LCC6 ascites to several cytotoxic drugs, including doxorubicin, etoposide (VP-16), BCNU and mitomycin C, closely reflects the activity of these single agents in previously untreated breast cancer patients. MDA435/LCC6 cells also retain the anchorage-dependent and anchorage-independent in vitro growth properties of the parental MDA-MB-435 cells, and can be used in standard in vitro drug screening assays. The drug resistance pattern of the MDA435/LCC6 cells suggests that they may have few active endogenous drug resistance mechanisms. To generate a model for the screening of MDR1-reversing agents, MDA435/LCC6 were transduced with a retroviral vector directing the constitutive expression of the MDR1 cDNA, producing a cell line with a classical MDR1 resistance pattern (MDA435/LCC6MDR1). THese ascites models may be a viable alternative to the murine leukaemia ascites (L1210, P388) and, in conjunction with other breast cancer cell lines, facilitate the in vitro and in vivo screening of new cytotoxic drugs and drug combinations.

Citing Articles

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells.

Zhou Y, Chung P, Ma J, Lam A, Law S, Chan K Biology (Basel). 2019; 8(4).

PMID: 31581572 PMC: 6955663. DOI: 10.3390/biology8040075.

Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery and .

Suffian I, Wang J, Faruqu F, Benitez J, Nishimura Y, Ogino C ACS Appl Nano Mater. 2019; 1(7):3269-3282.

PMID: 30613831 PMC: 6312360. DOI: 10.1021/acsanm.8b00480.

Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments.

Wan X, Beaudoin J, Vinod N, Min Y, Makita N, Bludau H Biomaterials. 2018; 192:1-14.

PMID: 30415101 PMC: 6331221. DOI: 10.1016/j.biomaterials.2018.10.032.

A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity.

He Z, Wan X, Schulz A, Bludau H, Dobrovolskaia M, Stern S Biomaterials. 2016; 101:296-309.

PMID: 27315213 PMC: 5035646. DOI: 10.1016/j.biomaterials.2016.06.002.

Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties.

Xiao M, Wang J, Lin Z, Lu Y, Li Z, White S PLoS One. 2015; 10(6):e0129807.

PMID: 26070194 PMC: 4466525. DOI: 10.1371/journal.pone.0129807.

References

Meschter C, Connolly J, Rose D . Influence of regional location of the inoculation site and dietary fat on the pathology of MDA-MB-435 human breast cancer cell-derived tumors grown in nude mice. Clin Exp Metastasis. 1992; 10(3):167-73. DOI: 10.1007/BF00132748. View

Clarke R, Dickson R, Lippman M . Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol. 1992; 12(1):1-23. DOI: 10.1016/1040-8428(92)90062-u. View

Leonessa F, Boulay V, Wright A, Thompson E, Brunner N, Clarke R . The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. Acta Oncol. 1992; 31(2):115-23. DOI: 10.3109/02841869209088890. View

Koh E, Chung H, Lee K, Lim H, Kim J, Roh J . The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Med J. 1992; 33(2):137-42. DOI: 10.3349/ymj.1992.33.2.137. View

Clarke R, Currier S, Kaplan O, LOVELACE E, Boulay V, Gottesman M . Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst. 1992; 84(19):1506-12. DOI: 10.1093/jnci/84.19.1506. View

Goldman C, Skinnider L, Maksymiuk A . Interferon instillation for malignant pleural effusions. Ann Oncol. 1993; 4(2):141-5. DOI: 10.1093/oxfordjournals.annonc.a058416. View

Botti G, Chiappetta G, DAiuto G, De Angelis E, De Matteis A, Montella M . PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori. 1993; 79(3):214-8. DOI: 10.1177/030089169307900312. View

Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R . Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res. 1994; 54(2):441-7. View

Zyad A, Benard J, Tursz T, Clarke R, Chouaib S . Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res. 1994; 54(3):825-31. View

10.

Veneroni S, Zaffaroni N, Daidone M, Benini E, Villa R, Silvestrini R . Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer. 1994; 30A(7):1002-7. DOI: 10.1016/0959-8049(94)90132-5. View

11.

Jonat W, Maass H . Some comments on the necessity of receptor determination in human breast cancer. Cancer Res. 1978; 38(11 Pt 2):4305-6. View

12.

CAILLEAU R, Olive M, Cruciger Q . Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 1978; 14(11):911-5. DOI: 10.1007/BF02616120. View

13.

Siciliano M, Barker P, CAILLEAU R . Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 1979; 39(3):919-22. View

14.

Ramu A, Glaubiger D, Fuks Z . Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 1984; 44(10):4392-5. View

15.

Miller A, Bulbrook R . UICC Multidisciplinary Project on Breast Cancer: the epidemiology, aetiology and prevention of breast cancer. Int J Cancer. 1986; 37(2):173-7. DOI: 10.1002/ijc.2910370202. View

16.

Batist G, Tulpule A, Sinha B, KATKI A, Myers C, Cowan K . Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986; 261(33):15544-9. View

17.

Pastan I, Gottesman M, Ueda K, LOVELACE E, Rutherford A, Willingham M . A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A. 1988; 85(12):4486-90. PMC: 280455. DOI: 10.1073/pnas.85.12.4486. View

18.

Garewal H . Mitomycin C in the chemotherapy of advanced breast cancer. Semin Oncol. 1988; 15(3 Suppl 4):74-9. View

19.

Singh L, Wilson A, Baum M, Whimster W, Birch I, Jackson I . The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. Br J Cancer. 1988; 57(6):612-4. PMC: 2246457. DOI: 10.1038/bjc.1988.139. View

20.

Vickers P, Dickson R, Shoemaker R, Cowan K . A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol. 1988; 2(10):886-92. DOI: 10.1210/mend-2-10-886. View